表紙
市場調査レポート

分子診断 (MDX) 市場の予測:主要企業にとっての市場機会

The Molecular Diagnostics (MDX) Market Forecast 2015-2025: Opportunities for Leading Companies

発行 Visiongain Ltd 商品コード 316201
出版日 ページ情報 英文 223 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=137.57円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
分子診断 (MDX) 市場の予測:主要企業にとっての市場機会 The Molecular Diagnostics (MDX) Market Forecast 2015-2025: Opportunities for Leading Companies
出版日: 2015年10月09日 ページ情報: 英文 223 Pages
概要

2019年の世界の分子診断市場は、104億5,000万ドルの規模に達すると予測されており、その後も急速に成長を遂げる見通しです。世界的な高齢化や癌などの慢性疾患の増加によって同市場は2025年まで成長する見込みです。

当レポートでは、世界の分子診断市場の現状と見通しについて調査し、分子診断の種類と概要、関連の法規制、その他の市場への影響因子の分析、検査区分別の市場収益の推移と予測、市場シェアの推移と予測、地域および主要国別の動向、主要企業のプロファイルなどをまとめています。

第1章 調査概要

第2章 イントロダクション:分子診断

  • インビトロ診断(IVD)検査とは
  • インビトロ診断の分類
  • IVDの下位市場
    • 臨床化学
    • 免疫化学
    • ポイントオブケア(POC)検査(血糖値自己検査も含む)
    • 分子診断
      • 感染症検査
      • 癌検査
      • 血液スクリーニング
      • 遺伝子検査
      • HLA判定
    • 臨床微生物学
    • 血液学/止血
  • IVD・MDx市場の法規制
    • FDA・CLIAとMDx検査
    • ECクラシフィケーション
    • 規制における10大課題
  • 医療機器物品税:診断関連メーカーへの脅威

第3章 インビトロ診断市場・分子診断部門の予測

  • IVD市場における分子診断
  • 世界のIVD市場の売上予測
  • IVD市場でシェアを拡大する分子診断

第4章 分子診断市場の予測:部門別

  • 分子診断市場の実績:部門別
  • 分子診断市場の推移と予測:部門別
    • 市場シェアの推移と予測
  • 感染症検査市場の予測
    • MDx感染症検査市場の内訳:疾患別
      • CT/NT
      • HPV検査
      • HIV
      • 医療関連感染(HAI)
      • C型肝炎(HCV)
      • 呼吸器感染
  • 癌検査市場の予測
    • 標的治療:癌検査市場の主な推進因子
    • 分子診断:現在はいくつかの適応症に限られる
      • 乳癌
      • 前立腺癌
      • 直腸癌
  • 血液スクリーニング市場の予測
    • GrifolsによるNovartis血液スクリーニング部門の買収
    • 主要製品
      • Cobas s 201 System (Roche Molecular)
      • Procleix Assays (Grifols)
  • 遺伝子検査市場の予測
    • 臨床的影響の分野別
    • より多くの適応症に拡大の可能性
    • 嚢胞性線維症
    • 第V因子ライデン・ 第II因子血栓発現傾向
    • 炎症性疾患
      • アルツハイマー病
      • リウマチ性関節炎
      • 希少疾患
  • 組織型判定(HLA)市場の予測
    • 次世代スクリーニング

第5章 主要国市場の予測

  • 地域別の内訳
  • 世界のMDx市場の予測
  • 地域別の市場シェア
  • 米国のMDx市場
  • 欧州のMDx市場の予測
    • 主要国市場のシェアの変化
    • 世界における主要な欧州市場のシェア
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 英国
    • その他
  • 日本のMDx市場の予測
  • 中国のMDx市場の予測
  • ブラジルのMDx市場の予測
  • ロシアのMDx市場の予測
  • インドのMDx市場の予測
  • 韓国のMDx市場の予測
  • メキシコのMDx市場の予測
  • その他の地域の市場の予測

第6章 主要企業

  • Roche Diagnostics
  • Qiagen
  • Hologic
  • Becton, Dickinson & Company
  • bioMerieux
  • Cepheid
  • Agilent Technologies

第7章 定性分析

  • MDx市場:成長推進因子・阻害因子
  • SWOT分析
  • ポーターのファイブフォース分析

第8章 調査インタビュー

第9章 総論

  • 分子診断市場:市場シェアの拡大
  • 分子診断:癌検査市場の成長
  • 分子診断市場の商業的成長推進因子
  • 分子診断市場の商業的成長疎外因子
  • 新興市場
  • まとめ

第10章 用語集

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0072

What can be expected from the Molecular Diagnostics market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects there.

Our 223-page report provides 145 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. You will see financial results, an interview, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2015-2025 and other analyses show you commercial prospects

Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter's Five Forces analysis) and commercial developments.

See revenue forecasts for the leading submarkets and indications

How will submarkets perform to 2025? Our study forecasts revenues in the following Molecular Diagnostics (MDx) submarkets:

  • Infectious disease testing
  • Oncology Testing
  • Blood screening
  • Genetic testing
  • Tissue Typing (HLA)

See revenue forecasts for the leading international markets

How will leading national markets perform to 2025? Our study forecasts revenues in national markets including products, including:

  • US
  • Japan
  • Germany
  • France
  • Italy
  • Spain
  • UK
  • China
  • Brazil
  • Russia
  • India
  • South Korea
  • Mexico

Leading companies and potential for market growth

Overall revenue for the Molecular Diagnostics (MDx) market will reach $10.45bn in 2019, our work forecasts. We predict strong revenue growth through to 2025. An ageing population and increasing incidence of chronic diseases, especially cancer, globally will drive sales to 2025.

Our work analyses the key companies in the market. See visiongain's analysis of 7 leading companies, including these:

  • Roche Diagnostics
  • Qiagen
  • Hologic
  • Becton, Dickinson & Company
  • bioMérieux
  • Cepheid
  • Agilent Technologies

A company profile gives you the following information where available:

  • Discussion of a company's activities and outlook
  • Analysis of assays and instruments currently on the market as well as pipeline products
  • Acquisitions and strategic partnerships

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect Molecular Diagnostics industry?

Our new report discusses issues and events affecting the Molecular Diagnostics market. You will find discussions, including qualitative analyses:

  • Highly diverse market needing strong knowledge of national markets
  • Unclear regulatory landscape challenging new entrants and major market players alike
  • Emerging technologies with the potential to reshape the market

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How The Molecular Diagnostics (MDx) Market Forecast 2015-2025 report helps you

In summary, our 223-page report gives you the following knowledge:

  • Revenue forecasts to 2025 for the Molecular Diagnostics (MDx) market - discover the industry's prospects, finding promising places for investments and revenues
  • Revenue forecasts to 2025 for submarkets in each - discover prospects for leading assays and instrumentation in the following areas: Infectious Disease testing including Chlamydia Trachonomatis (CT), Neisseriae Gonnohroea (NG), Human Papillomavirus (HPV), HIV, Healthcare associated infections (MRSA & Clostridium Difficile) Hepatitis C (HCV) and Respiratory infections (including Influenza and RSV), Oncology Testing and companion diagnostics, Blood Screening, Genetic Testing (including Cystic Fibrosis testing, Thrombophilia testing, inflammatory disease testing and rare disease testing) and Tissue (HLA) typing.
  • Revenue forecasts to 2025 for the leading regional markets - US, Japan, EU5, BRIC South Korea and Mexico
  • Assessment of 7 leading companies - analysis of Molecular Diagnostic products, revenue, mergers & acquisitions, sales by region and upcoming product releases
  • Discussion of what stimulates and restrains companies and the market
  • Prospects for established firms and those seeking to enter the market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the Molecular Diagnostics market and leading companies. You will find data, trends and predictions. Please order our report now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. The Molecular Diagnostics Market Overview
  • 1.2. Molecular Diagnostics Market Segmentation
  • 1.3. Why You Should Read This Report
  • 1.4. How This Report Delivers
  • 1.5. Key Questions Answered by This Analytical Report
  • 1.6. Who is This Report For?
  • 1.7. Methodology
  • 1.8. Frequently Asked Questions (FAQ)
  • 1.9. Associated Reports
  • 1.10. About visiongain

2. Introduction to Molecular Diagnostics

  • 2.1. What are In Vitro Diagnostic (IVD) Tests?
  • 2.2. Classifying In Vitro Diagnostics
    • 2.2.1. FDA Classifications
    • 2.2.2. The EC (European Commission) Classification
    • 2.2.3. IVD Classification in Australia
  • 2.3. IVD Submarkets
    • 2.3.1. Clinical Chemistry
    • 2.3.2. Immunochemistry
    • 2.3.3. Point-of-care Testing (Including Self-Monitoring Blood Glucose Tests)
    • 2.3.4. Molecular Diagnostics
      • 2.3.4.1. Infectious Disease Testing
      • 2.3.4.2. Oncology Testing
      • 2.3.4.3. Blood Screening
      • 2.3.4.4. Genetic Testing
      • 2.3.4.5. Tissue Typing (HLA Testing)
    • 2.3.5. Clinical Microbiology
    • 2.3.6. Haematology/ Haemostasis
  • 2.4. Regulation of the IVD and MDx Market
    • 2.4.1. FDA and CLIA Regulation of IVD and MDx Tests
    • 2.4.2. Regulation of IVD/MDx Tests in the EU: The EC (European Commission) Classification
    • 2.4.3. Top Ten Challenges in Regulation for In-Vitro Diagnostics
      • 2.4.3.1. Challenges in Regulations of MDx Tests
  • 2.5. Device Excise Tax: A Threat to the Diagnostics Manufacturers

3. The Molecular Diagnostics Segment within the In Vitro Diagnostics Market, 2015-2025

  • 3.1. Molecular Diagnostics in the IVD Market, 2014
  • 3.2. Sales Forecast for the Global IVD Market 2015-2025
  • 3.3. Molecular Diagnostics Gaining A Greater Share of the IVD Market

4. The Molecular Diagnostics Market by Sectors, 2015-2025

  • 4.1. The Molecular Diagnostic Market by Sectors, 2014
  • 4.2. The Molecular Diagnostic Market by Sectors 2015-2025
    • 4.2.1. Market Shares of the Molecular Diagnostics Sectors 2015-2025
  • 4.3. The Infectious Disease Testing Market 2015-2025
    • 4.3.1. Breakdown of the MDx Infectious Disease Testing Market by Disease, 2014
      • 4.3.1.1. CT/NG
      • 4.3.1.2. HPV Testing
      • 4.3.1.3. HIV
      • 4.3.1.4. Healthcare Associated Infections (HAI)
      • 4.3.1.5. Hepatitis C (HCV)
      • 4.3.1.6. Respiratory Infections
  • 4.4. The Oncology Testing Market, 2015-2025
    • 4.4.1. Targeted Therapies: A Major Driver of the Oncology Testing Market
    • 4.4.2. Molecular Diagnostics: Currently Concentrated on a Few Cancer Indications
      • 4.4.2.1. Breast Cancer
      • 4.4.2.2. Prostate Cancer
        • 4.4.2.2.1. Prostate Cancer Pipeline Biomarkers
          • 4.4.2.2.1.1. TMPRSS2-ERG (OriGene)
          • 4.4.2.2.1.2. PTEN
      • 4.4.2.3. Colorectal Cancer
  • 4.5. The Blood Screening Market 2015-2025
    • 4.5.1. Grifols' Acquisition of Novartis's Blood Screening Unit
    • 4.5.2. Leading Blood Screening Test Products
      • 4.5.2.1. Cobas s 201 System (Roche Molecular)
      • 4.5.2.2. Procleix Assays (Grifols)
  • 4.6. The Genetic Testing Market 2015-2025
    • 4.6.1. Genetic Testing by Clinical Impact Area
    • 4.6.2. Genetic Testing: Potential beyond Oncology
    • 4.6.3. Cystic Fibrosis
    • 4.6.4. Factor V Leiden and Factor II Thrombophilia
    • 4.6.5. Inflammatory Diseases
      • 4.6.5.1. Alzheimer's Disease (AD)
      • 4.6.5.2. Rheumatoid Arthritis
        • 4.6.5.2.1. Vectra®DA (Crescendo Bioscience)
        • 4.6.5.2.2. Quest Diagnostics: Biomarker Study
      • 4.6.5.3. Rare Diseases
  • 4.7. The Tissue Typing (HLA Typing) Market 2015-2025
    • 4.7.1. Tissue Typing: Next-Generation Sequencing

5. The Leading Molecular Diagnostics National Markets, 2015-2025

  • 5.1. Regional Breakdown of the Global MDx Market, 2014
  • 5.2. The Global MDx Market Forecast, 2015-2025
  • 5.3. The Regional Market Shares of the MDx Market, 2014, 2019 and 2025
  • 5.4. The US MDx Market 2014
    • 5.4.1. The US MDx Market Forecast 2015-2025
      • 5.4.1.1. United States: Diagnostic Reimbursement
  • 5.5. The European MDx Markets Forecast 2015-2025
    • 5.5.1. Changes in the Shares of the Leading European Markets, 2014, 2019 and 2025
    • 5.5.2. Shares of the Major European Markets in a Global Context
    • 5.5.3. The German MDx Market Forecast 2015-2025
    • 5.5.3The French MDx Market Forecast 2015-2025
    • 5.5.4. The Italian MDx Market Forecast 2015-2025
    • 5.5.5. The Spanish MDx Market Forecast 2015-2025
    • 5.5.6. The UK MDx Market Forecast 2015-2025
    • 5.5.7. The Other European MDx Markets Forecast 2015-2025
  • 5.6. The Japanese MDx Market Forecast 2015-2025
  • 5.7. The Chinese MDx Market Forecast 2015-2025
    • 5.7.1. China: Increasing Cancer Burden
  • 5.8. The Brazilian MDx Market Forecast 2015-2025
  • 5.9. The Russian MDx Market Forecast 2015-2025
  • 5.10. The Indian MDx Market Forecast 2015-2025
    • 5.10.1. India: Expansion of Healthcare Provisions
  • 5.11. The South Korean MDx Market Forecast 2015-2025
  • 5.12. The Mexican MDx Market Forecast 2015-2025
  • 5.13. The Rest of the World Market Forecast 2015-2025

6. The Leading Companies in the Molecular Diagnostics Market, 2015

  • 6.1. Roche Diagnostics
    • 6.1.1. Roche: Global Presence
    • 6.1.2. Roche Diagnostics, 2015-2025
    • 6.1.3. Roche Diagnostics Business Performance within the IVD Market, 2014
      • 6.1.3.1. Molecular Diagnostics Sales Performance, 2014
      • 6.1.3.2. Molecular Diagnostic Sales by Region, 2014
    • 6.1.4. Roche Diagnostics: MDx Product Launches and Indication Expansion, 2015
      • 6.1.4.1. Roche Diagnostics: Product Launch Plans, 2015
    • 6.1.5. Roche: Major M&A Activity and Strategic Partnerships Strengthen Position as Market Leader
      • 6.1.5.1. Genia Acquisition to Strengthen DNA Sequencing Capabilities
      • 6.1.5.2. IQuum Acquisition Allows Movement into POC MDx Market
      • 6.1.5.3. Seragon Acquisition Strengthens Leading Position in Oncology
      • 6.1.5.4. Santaris Acquisition Enchances Roche's Position in RNA-Targeted Drugs Market
      • 6.1.5.5. Bina Acquisition Brings Big Data Solution to Support NGS Development
      • 6.1.5.6. Dutalys Acquisition Enhances Roche's mAB Portfolio
      • 6.1.5.7. Ariosa Acquisition Adds NIPT to MDx Portfolio
      • 6.1.5.8. Foundation Medicine Deal Enhances Personalised Medicine Capabilities for Oncology
      • 6.1.5.9. Signature and CAPP Acquisitions Strengthen Circulating DNA Testing Abilities
      • 6.1.5.10. GENEWEAVE and Kapa Acquisitions Help Cement Roche's Position as the MDx Market Leader
  • 6.2. Qiagen NV
    • 6.2.1. Sales and Recent Performance Analysis, 2014
    • 6.2.2. Qiagen Sales by Region, 2014
    • 6.2.3. Qiagen Sales by Segment, 2014
    • 6.2.4. Qiagen: Molecular Diagnostics
    • 6.2.5. Molecular Diagnostics: Product Expansion
      • 6.2.5.1. QIASymphony
      • 6.2.5.2. QuantiFERON-TB Gold: Expansion into Asia
      • 6.2.5.3. Personalised Healthcare: Collaborative Efforts
      • 6.2.5.4. Qiagen's Software Company Acquisitions Cement Leadership in Bioinformatics
  • 6.3. Hologic
    • 6.3.1. Hologic Recent Sales Performance by Business Segment, 2014
    • 6.3.2. Hologic Molecular Diagnostics: Product Portfolio
  • 6.4. Becton, Dickinson and Company
    • 6.4.1. Sales and Financial Performance, 2014
    • 6.4.2. Sales and Financial Performance by Region, 2014
    • 6.4.3. Becton, Dickinson and Company Diagnostics Sales and Financial Performance, 2013-2014
    • 6.4.4. BD Diagnostics: Product Portfolio
    • 6.4.5. BD Diagnostics: Mergers and Acquisitions
  • 6.5. bioMérieux
    • 6.5.1. Sales and Recent Performance Analysis, 2010-2014
    • 6.5.2. Sales by Region, 2014
    • 6.5.3. Sales by Technology, 2014
    • 6.5.4. Molecular Diagnostics: Product Portfolio
    • 6.5.5. Companion Diagnostics: Collaborations with GSK and Novartis
    • 6.5.6. Mergers, Acquisitions and Collaborations
    • 6.5.7. bioTheranostics: Subsidiary for Oncology Diagnostics
  • 6.6. Cepheid
    • 6.6.1. Sales and Recent Performance Analysis, 2010-2014
    • 6.6.2. Sales by Industry Segment, 2013-2014
    • 6.6.3. Sales by Region, 2012-2014
    • 6.6.4. Cepheid: Product Line
    • 6.6.5. Cepheid: Business strategy
  • 6.7. Agilent Technologies
    • 6.7.1. Sales and Recent Performance Analysis, 2014
    • 6.7.2. Sales Performance by Business Segment, 2014
    • 6.7.3. Agilent Technologies: Strong Player in Target Enrichment for Next-Generation Sequencing

7. Qualitative Analysis of the MDx Market, 2015-2025

  • 7.1. MDx Market: Drivers and Restraints
  • 7.2. SWOT Analysis of the MDx Market, 2015-2025
    • 7.2.1. Strengths
      • 7.2.1.1. Patient Demographics
      • 7.2.1.2. Increased Awareness
      • 7.2.1.3. High Growth in Oncology Molecular Diagnostics
      • 7.2.1.4. Increasing Laboratory Test Menus
      • 7.2.1.5. Personalised Medicine: Optimising Treatment Outcomes
    • 7.2.2. Weaknesses
      • 7.2.2.1. Lack of Clear Regulatory Guidelines for Molecular Diagnostics
      • 7.2.2.2. Reimbursement Challenges for Molecular Diagnostic Companies
      • 7.2.2.3. Consolidation of Healthcare Systems Increases Pricing Pressure
      • 7.2.2.4. MDx: An Expensive, but Undervalued Diagnostic Tool
    • 7.2.3. Opportunities
      • 7.2.3.1. Next-Generation Sequencing
      • 7.2.3.2. Emerging Markets
      • 7.2.3.3. The Emergence of New Microorganisms
    • 7.2.4. Threats
      • 7.2.4.1. US Medical Device Excise Tax
      • 7.2.4.2. Gene Patents: Controversial Ruling
  • 7.3. Porter's Five Forces Analysis of the MDx Market
    • 7.3.1. Rivalry among Competitors [High]
    • 7.3.2. Threat of New Entrants [Medium]
    • 7.3.3. Power of Suppliers [Medium]
    • 7.3.4. Power of Buyers [High]
    • 7.3.5. Threat of Substitutes [High]

8. Research Interview

  • 8.1. Kai te Kaat, Vice President, Global Product Management Life Sciences, Head of NGS Program, QIAGEN NV
    • 8.1.1. QIAGEN: Pioneers in NGS Technology
    • 8.1.2. The Future of NGS Outside Oncology
    • 8.1.3. QIAGEN: Leading Progress in Bioinformatics
    • 8.1.4. Regional Demand for NGS and NGS in the Wider Diagnostics Market

9. Conclusion

  • 9.1. The Molecular Diagnostics Market: Growing Market Share
  • 9.2. Molecular Diagnostics: Oncology Testing Market Growth
  • 9.3. Commercial Drivers of the Molecular Diagnostics Market
  • 9.4. Commercial Restraints of the Molecular Diagnostics Market
  • 9.5. Emerging Markets
  • 9.6. Concluding Remarks

10. Glossary

List of Tables

  • Table 1.1: Molecular Diagnostics Leading National Markets Forecast: Revenues ($bn), AGR (%) and CAGR (%), 2014-2025
  • Table 2.1: Advantages and Disadvantages of POC Diagnostics, 2015
  • Table 3.1: World IVD Market: Revenues ($bn) and Market Share (%) by Segment, 2014
  • Table 3.2: World IVD Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Segment, 2014-2025
  • Table 3.3: Market Shares (%) of MDx in the IVD Market, 2014, 2019 & 2025
  • Table 4.1: The MDx Market: Revenues ($bn) and Market Shares (%) by Segment, 2014
  • Table 4.2: The Global MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Segment, 2014-2025
  • Table 4.3: The MDx Market: Market Shares (%) by Segment, 2014, 2019 and 2025
  • Table 4.4: The Infectious Disease Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
  • Table 4.5: The Infectious Disease Testing Market: Revenues ($bn) and Market Share (%) by Disease, 2014
  • Table 4.6: Selected FDA and CE-Approved Molecular Diagnostics Test for CT/NG, 2015
  • Table 4.7: Selected FDA and CE-Approved Molecular Diagnostics Test for HPV, 2015
  • Table 4.8: Selected FDA and CE-Approved Molecular Diagnostics Tests for HIV, 2015
  • Table 4.9: Selected FDA and CE-Approved Molecular Diagnostics Test for HAIs, 2015
  • Table 4.10: Selected FDA and CE-Approved Molecular Diagnostics Tests for HCV, 2015
  • Table 4.11: Selected FDA-Approved Molecular Diagnostics Test for Respiratory Infections, 2015
  • Table 4.12: The Oncology Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
  • Table 4.13: Examples of Clinically Relevant Cancer Biomarkers Tied with a Drug, 2015
  • Table 4.14: Selected List of FDA-Approved MDx Tests for Breast Cancer, 2015
  • Table 4.15: Selected List of FDA-Approved MDx Tests for Prostate Cancer, 2015
  • Table 4.16: Selected List of FDA-Approved MDx tests for Colorectal Cancer, 2015
  • Table 4.17: The Blood Screening Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
  • Table 4.18: The Genetic Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
  • Table 4.19: Selected Genetic Tests for Cystic Fibrosis on the Market, 2015
  • Table 4.20: Selected Genetic Tests for Factor V Leiden/Factor II Thrombophilia on the Market, 2015
  • Table 4.21: Selected Alzheimer's MDx Diagnostic Tests in Development, 2015
  • Table 4.22: The Tissue Typing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
  • Table 4.23: Selected tissue typing Kits on the Market, 2015
  • Table 5.1: The MDx Market: Revenue ($bn) and Market Share (%) by Region, 2014
  • Table 5.2: The MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Region, 2014-2025
  • Table 5.3: The MDx Market: Market Shares (%) by Regional Markets, 2014, 2019 and 2025
  • Table 5.4: The US MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
  • Table 5.5: The European MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
  • Table 5.6: The European MDx Market: Market Shares (%) by Country, 2014, 2019 and 2025
  • Table 5.7: The German MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
  • Table 5.8: The French MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
  • Table 5.9: The Italian MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
  • Table 5.10: The Spanish MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
  • Table 5.11: The UK MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
  • Table 5.12: The Other European MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
  • Table 5.13: The Japanese MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
  • Table 5.14: The Chinese MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
  • Table 5.15: The Brazilian MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
  • Table 5.16: The Russian MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
  • Table 5.17: The Indian MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
  • Table 5.18: The South Korean MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
  • Table 5.19: The Mexican MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
  • Table 5.20: The Rest of the World MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
  • Table 6.1: Roche Diagnostics: Revenue ($bn) and Revenue Share (%) by Business Area, 2014
  • Table 6.2: Roche Molecular Diagnostics: Revenue ($bn), Revenue Shares (%) by Region, 2014
  • Table 6.3: Roche Diagnostics: Key Product Launches (Instruments/Devices) Planned for 2015
  • Table 6.4: Roche Diagnostics: Key Product Launches (Tests/Assays) Planned for 2015
  • Table 6.5: Qiagen: Revenue ($m) and Revenue Share (%) by Region, 2012-2014
  • Table 6.6: Hologic: Revenue ($bn) and Revenue Share (%) by Segment, 2012-2014
  • Table 6.7: Hologic: Diagnostics Revenue ($bn) and Revenue Share (%) by Segment, 2014
  • Table 6.8: Becton, Dickinson and Company: Revenue ($bn) and AGR (%) by Region, 2012-2014
  • Table 6.9: Becton, Dickinson and Company: Sales ($bn), AGR (%) by Diagnostics Division, 2013-2014
  • Table 6.10: bioMérieux : Revenue ($bn) and AGR (%), 2010-2014
  • Table 6.11: bioMérieux: Revenue ($m) and Revenue Change (%) by Region, 2013-2014
  • Table 6.12: bioMérieux: Revenue ($bn) and Revenue Share (%) by Region, 2014
  • Table 6.13: bioMérieux: Revenue ($bn) and Revenue Change (%) by Technology, 2013-2014
  • Table 6.14: Cepheid: Revenue ($m) and Net Income ($m), 2010-2014
  • Table 6.15: Cepheid: Revenue ($m) and AGR (%) by Industry, 2012-2014
  • Table 6.16: Cepheid: Revenue ($m), AGR (%) and CAGR (%) by Region and Industry, 2012-2014
  • Table 6.17: Agilent Technologies: Revenue ($bn) and AGR (%), 2010-2014
  • Table 6.18: Agilent Technologies: Revenue ($bn) and AGR (%) by Business Segment, 2010-2014
  • Table 6.19: Agilent Technologies Life Sciences and Diagnostics: Revenue ($bn) by Segment, 2012-2014
  • Table 7.1: SWOT Analysis of the Global MDx Market, 2015-2025
  • Table 9.1: MDx and Other In Vitro Diagnostics: World Revenue ($bn) Forecast, 2014, 2019 and 2025

List of Figures

  • Figure 1.1: Molecular Diagnostics: Overview of Submarkets
  • Figure 3.1: World IVD Market: Revenues ($bn) by Segment, 2014
  • Figure 3.2: World IVD Market: Revenue Shares (%) by Segment, 2014
  • Figure 3.3: World IVD Market Forecast: Revenue ($bn) and AGR (%) by Segment, 2014-2025
  • Figure 3.4: World MDx Market Share (%) in the IVD Market, 2019
  • Figure 3.5: World MDx Market Share (%) in the IVD Market, 2025
  • Figure 4.1: The MDx Market Shares (%) by Sector in the IVD Market, 2014
  • Figure 4.2: The MDx Market: Revenue ($bn) by Segment, 2014
  • Figure 4.3: The MDx Market: Market Shares (%) by Segment, 2014
  • Figure 4.4: The Global MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
  • Figure 4.5: The MDx Market: Market Shares (%) by Segment, 2019
  • Figure 4.6: The MDx Market: Market Shares (%) by Segment, 2025
  • Figure 4.7: The Infectious Disease Testing Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
  • Figure 4.8: The Infectious Disease Testing Market: Market Shares (%) by Disease, 2014
  • Figure 4.9: The Oncology Testing Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
  • Figure 4.10: The Cancer Treatment Sequence and the Application of Molecular Diagnostics and Companion Diagnostics
  • Figure 4.11: The Blood Screening Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
  • Figure 4.12: The Genetic Testing Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
  • Figure 4.13: The Genetic Testing Market by Clinical Impact Area, 2014
  • Figure 4.14: The Tissue Typing Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
  • Figure 5.1: The MDx Market: Market Shares (%) by Region, 2014
  • Figure 5.2: The MDx Market: Revenue ($bn) by Region, 2014
  • Figure 5.3: The MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
  • Figure 5.4: The MDx Market: Market Shares (%) by Region, 2019
  • Figure 5.5: The MDx Market: Market Shares (%) by Region, 2025
  • Figure 5.6: The US MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
  • Figure 5.7: The European MDx Market Forecast: Revenue ($bn) by Region, AGR (%), 2014-2025
  • Figure 5.8: The European MDx Market: Market Shares (%) by Country, 2014
  • Figure 5.9: The European MDx Market: Market Shares (%) by Country, 2019
  • Figure 5.10: The European MDx Market: Market Shares (%) by Country, 2025
  • Figure 5.11: Europe in The Global MDx Market: Market Shares (%) by Country, 2014
  • Figure 5.12: Europe in The Global MDx Market: Market Shares (%) by Country, 2019
  • Figure 5.13: Europe in The Global MDx Market: Market Shares (%) by Country, 2025
  • Figure 5.14: The German MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
  • Figure 5.15: The French MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
  • Figure 5.16: The Italian MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
  • Figure 5.17: The Spanish MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
  • Figure 5.18: The UK MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
  • Figure 5.19: The Other European MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
  • Figure 5.20: The Japanese MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
  • Figure 5.21: The Chinese MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
  • Figure 5.22: The Brazilian MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
  • Figure 5.23: The Russian MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
  • Figure 5.24: The Indian MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
  • Figure 5.25: The South Korean MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
  • Figure 5.26: The Mexican MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
  • Figure 5.27: The Rest of the World MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
  • Figure 6.1: Roche Diagnostics: Revenues ($bn) by Business Area, 2014
  • Figure 6.2: Roche Diagnostics: Revenue Share (%) by Business Area, 2014
  • Figure 6.3: Roche Molecular Diagnostics: Revenue Share (%) by Region, 2014
  • Figure 6.4: Qiagen:Revenue ($bn), Net Income ($bn) and Profit Margin (%), 2010-2014
  • Figure 6.5: Qiagen: Revenue ($m) by Region, 2014
  • Figure 6.6: Qiagen: Revenue Share (%) by Region, 2014
  • Figure 6.7: Hologic: Revenue ($bn) by Business Segment, 2012-2014
  • Figure 6.8: Hologic: Revenue Share (%) by Business Segment, 2014
  • Figure 6.9: Hologic: Diagnostics Revenue Share (%) by Business Segment, 2014
  • Figure 6.10: Becton, Dickinson and Company: Revenue Share (%) by Segment, 2014
  • Figure 6.11: Becton, Dickinson and Company: Revenue ($bn) by Region, 2012-2014
  • Figure 6.12: Becton, Dickinson and Company: Revenue Share (%) by Region, 2014
  • Figure 6.13: Becton, Dickinson and Company: Revenue Share (%) by Diagnostics Division, 2014
  • Figure 6.14: bioMérieux: Revenue ($m) and AGR (%), 2010-2014
  • Figure 6.15: bioMérieux: Revenue ($bn) by Region, 2014
  • Figure 6.16: bioMérieux: Revenue Share (%) by Region, 2014
  • Figure 6.17: bioMérieux: Revenue Share (%) by Technology, 2014
  • Figure 6.18: Cepheid: Revenue ($m) and Net Income ($m), 2010-2014
  • Figure 6.19: Cepheid: Revenue Share (%) by Industry, 2014
  • Figure 6.20: Cepheid: Revenue Share (%) by Region, 2012
  • Figure 6.21: Cepheid: Revenue Share (%) by Region, 2014
  • Figure 6.22: Agilent Technologies: Revenue ($bn) and AGR (%), 2010-2014
  • Figure 6.23: Agilent Technologies: Revenue Share (%) by Business Segment, 2014
  • Figure 6.24: Agilent Technologies Life Sciences and Diagnostics: Revenue Share (%) by Segment, 2014
  • Figure 7.1: MDx Market: Drivers and Restraints, 2015-2025
  • Figure 7.2: The Global Over 65 Population: Forecast (millions, AGR%), 2014-2025
  • Figure 7.3: Porter's Five Forces Analysis of the MDx Market, 2015-2025
  • Figure 9.1: MDx and Other In Vitro Diagnostics: World Revenue ($bn) Forecast, 2014, 2019 and 2025
  • Figure 9.2: Molecular Diagnostics Market Forecast: AGRs (%) in the US, India, China and Global Market, 2014-2025

Companies Listed

  • Abbott Laboratories / Abbott Molecular
  • AdvanDx
  • Agilent Technologies
  • Alere
  • ArcherDx
  • ARGENE
  • Ariosa Diagnostics
  • Atria Genetics
  • Astute Medical
  • Autogenomics, Inc.
  • AvariaDx
  • Becton, Dickinson & Co. / BD Diagnostics
  • Bina Technologies, Inc.
  • BIOBASE
  • Biocartis
  • BioFire Diagnostics
  • bioMérieux
  • Bio-Reference Laboratories
  • bioTheranostics
  • Boehringer Ingelheim
  • Bristo Myers Squibb
  • CAPP Medical
  • Celera Diagnostics
  • Cepheid
  • Chugai Pharmaceuticals
  • Clarient
  • CLC Bio.
  • Cognoptix
  • COPAN
  • Crescendo Bioscience
  • Dako A/S
  • Danaher Corporation
  • DiaGenic
  • DiagnoCure
  • Dutalys
  • DxS
  • EliTechGroup Epoch Biosciences
  • Enzymatics
  • Exact Sciences Corporation
  • Exosome
  • Focus Diagnostics, Inc.
  • Foundation Medicine
  • GE Healthcare
  • GenCell Biosystems
  • Genia Technologies, Inc.
  • Genentech
  • Genomic Health
  • GeneWEAVE Biosciences, Inc.
  • Gen-Probe
  • Gilead Sciences
  • Great Basin Scientific, Inc.
  • Grifols
  • Hain Lifescience
  • HandyLab
  • Hologic
  • IGEN International
  • Illumina, Inc.
  • Ingenuity Systems
  • Infectio Diagnstic, Inc.
  • Intelligent Medical Devices, Inc.
  • Ipsogen
  • IQuum, Inc.
  • IRIS International, Inc.
  • Janssen Diagnostics, LLC
  • Kapa Biosystems
  • Keysight Technologies Inc.
  • KIESTRA Lab Automation BV
  • Luminex Molecular Diagnostics, Inc.
  • MDx Health
  • Merck
  • Meridian Bioscience, Inc.
  • Meso Scale Diagnsotics
  • Myriad Genetic Laboratories, Inc.
  • Nanosphere, Inc.
  • Nanostring Technologies
  • Novartis
  • Olerup SSP AB
  • One Lambda
  • OPKO
  • OriGene
  • Ortho Clinical Diagnostics
  • Osmetech Molecular Diagnostics
  • PrimeraDx
  • Prodesse, Inc.
  • Proteome Sciences
  • Qiagen
  • Quest Diagnostics, Inc.
  • Quidel Corporation
  • RAS Lifesciences Pvt. Ltd
  • Roche Diagnostics (F. Hoffmann-La Roche Ltd.)
  • Saladax Biomedical Inc.
  • Santaris Pharma A/S
  • Seragon Pharmaceuticals, Inc.
  • Siemens Healthcare Diagnostics
  • Signature Diagnostics AG
  • Texas BioGene Inc.
  • Thermo Fisher Scientific
  • Ventana Medical Systems, Inc.
  • Veridex, LLC

Organisations Mentioned in the Report

  • American Medical Association
  • FDA's Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)
  • French Court of Auditors
  • National Institute for Health and Clinical Excellence (NICE)
  • Rospotrebnadzor Federal Monitoring Agency
  • Rashtriya Swasthya Bima Yojana (RSBY) - (Indian National Health Insurance Programme)
  • Seguro Popular (Mexican National Health Insurance Programme)
  • United Nations Population Division
  • US Centers for Disease Control and Prevention (CDC)
  • US Centers for Medicare and Medicaid Services (CMS)
  • US Congressional Research Service (CRS)
  • US Food and Drug Administration (FDA)
  • USPS (United States Postal Service)
  • US National Healthcare Safety Network (NHSN)
  • World Health Organisation (WHO)
Back to Top